Business
HeartBeam Announces Closing of $10 Million Public Offering of Common Stock
Offering was led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors SANTA
About this update from Heartbeam, Inc.
[{"type":"text","content":"\nOffering was led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors\n\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it has closed its underwritten public offering of 12,500,000 shares of common stock for total gross proceeds of $10 million before deducting underwriting discounts, commissions, and offering expenses. The closing of the offering occurred on April 16, 2026.\n\n\nThe offering was led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.\n\n\nHeartBeam intends to use the net proceeds received from the offering to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, further enhance its AI capabilities, and for working capital and general corporate purposes.\n\n\nTitan Partners, a division of American Capital Partners, acted as the sole bookrunner for the offering.\n\n\nThis offering was made by HeartBeam pursuant to a shelf registration statement on Form S-3/A (File No. 333-293307) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 13, 2026, which became effective on March 17, 2026. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement was filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at [email protected].\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws...